More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline...( - Tasigna front-line data demonstrati...),Health

- Tasigna front-line data demonstrating potential in newly diagnosed patients with a life-threatening type of leukemia to be featured in two oral sessions at ASH

- Exjade results at ASH to show benefits for chronically transfused patients by significantly reducing toxic iron that can damage key organs

- New long-term data from major independent breast cancer trial at SABCS to report on optimal post-surgery treatment strategy, Femara vs. tamoxifen

- Multiple Zometa studies at SABCS to affirm anti-cancer activity in patients with early-stage breast cancer

EAST HANOVER, N.J., Dec. 4 /PRNewswire/ -- More than 200 abstracts from therapies across the Novartis Oncology portfolio will be presented at two December medical congresses, providing new data and profiling potential patient benefits from ongoing collaboration with the oncology community.

The American Society of Hematology (ASH) annual meeting, beginning December 6th in San Francisco, CA, will feature 34 oral presentations on the Novartis Oncology portfolio including 20 on Gleevec(R) (imatinib mesylate) tablets, six on Tasigna(R) (nilotinib) capsules, five on Exjade(R) (deferasirox) and three on products in development. The CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), beginning December 10th, will feature four oral presentations, including three on Femara(R) (letrozole tablets) and one on Zometa(R) (zoledronic acid) injection.

"Our robust portfolio and dedication to oncology research is ultimately about providing patients and their physicians with new treatment options to address unmet medical needs," said David Epstein, CEO and President of Novartis Oncology. "We are pleased that our ongoing work with experts in the fields of oncology and hematology continue to provide valuable new insights across multiple cancer types."

The most significant presentations
'/>"/>